Keywords: China, AstraZeneca, Manufacturing plant, Investment, Novo Nordisk, Victoza, Type 2 diabetes, Launch, New drug approvals

AstraZeneca to investment $200 million in Chinese manufacturing plant; Novo Nordisk debuts Victoza

Article | 10 October 2011

Print This

Anglo-Swedish drug major AstraZeneca ILSE: AZN) said this morning that it is investing $200 million in a new manufacturing facility, located ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in